ArticleAvicenna journal of phytomedicine
Arbutin attenuates behavioral impairment and oxidative stress in an animal model of Parkinson's disease.
Article in Avicenna journal of phytomedicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 39 citations in OpenAlex.
- Role of arbutin and acetoside against Parkinson's disease.Indian journal of pharmacology · 2026Review
- Arbutin attenuates aluminium chloride-induced neurotoxicity and cognitive deficits in a zebrafish model of Alzheimer's disease.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Evaluation of the protective effect of Benfotiamine against neurotoxic effects, depression and oxidative stress induced by noise exposure.Scientific reports · 2025Article
- Arbutin's Potential in Neuroprotection: A Promising Role in Mitigating Neurodegenerative Diseases.Current drug research reviews · 2025Review
- Article
- Targeting JAK2/STAT3, NLRP3/Caspase-1, and PK2/PKR2 Pathways with Arbutin Ameliorates Lead Acetate-Induced Testicular Injury in Rats.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Protective effects of arbutin against doxorubicin-induced cardiac damage.Molecular biology reports · 2024Article
- The prevention of home-cage grid climbing affects muscle strength in mice.Scientific reports · 2022Article
- Arbutin effectively ameliorates the symptoms of Parkinson's disease: the role of adenosine receptors and cyclic adenosine monophosphate.Neural regeneration research · 2021Article
- Behavioral Assessment of Sensory, Motor, Emotion, and Cognition in Rodent Models of Intracerebral Hemorrhage.Frontiers in neurology · 2021Review
- The Effect of Arbutin on The Expression of Tumor SuppressorCell journal · 2021Article
- Insights into Arbutin Effects on Bone Cells: Towards the Development of Antioxidant Titanium Implants.Antioxidants (Basel, Switzerland) · 2020Article
- Arbutin Improves Functional Recovery and Attenuates Glial Activation in Lysolecethin-Induced Demyelination Model in Rat Optic Chiasm.Molecular neurobiology · 2020Article
- Alpha-Arbutin Promotes Wound Healing by Lowering ROS and Upregulating Insulin/IGF-1 Pathway in Human Dermal Fibroblast.Frontiers in physiology · 2020Article
- Neuroprotective effects of protocatechuic aldehyde through PLK2/p-GSK3β/Nrf2 signaling pathway in bothAging · 2019Article
- Arbutin attenuates nephrotoxicity induced by gentamicin.Avicenna journal of phytomedicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveArbutin has been shown to have antioxidant and free-radical scavenging properties. The aim of this study was to investigate the effects of arbutin administration on behavioral impairment, and oxidative and nitrosative stress in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced animal model of Parkinson's disease (PD). MATERIALS AND
methodsPD model was developed by 4 intraperitoneal (i.p.) injections of MPTP (20 mg/kg) with 2 h intervals in mice. Experimental groups received once daily injection of saline as vehicle (control group) or arbutin (50 mg/kg, i.p.) one week before MPTP injections and this protocol was continued seven days post lesion. Behavioral deficits were evaluated using locomotion test, hanging wire test and forepaw stride length. Parameters indicating the oxidation levels including lipid peroxidation marker (TBARS), nitrite, protein carbonyl levels and antioxidant activity including ferric reducing antioxidant power (FRAP) were assessed in serum and midbrain samples.
resultsTreatment with arbutin improved motor functions in an MPTP-induced PD model compared to control group (p<0.001). Mice treated with MPTP showed reduced levels of FRAP (p<0.001) and increased levels of TBARS (p<0.001), nitrite (p<0.001) and protein carbonyl (p<0.01), compared to the control group. In contrast to the MPTP group, arbutin treatment decreased the levels of TBARS (p<0.05), nitrite (p<0.05), protein carbonyl (p<0.05), and increased FRAP levels (p<0.05) in mice with PD.
conclusionThese findings suggest that arbutin attenuates the behavioral impairment and oxidative stress in a PD animal model.
Indexed as
Identifiers
30456201PMC6235658W2895817064What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.